These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28109629)

  • 21. Assessing the impact of clinical pharmacists on naloxone coprescribing in the primary care setting.
    Watson A; Guay K; Ribis D
    Am J Health Syst Pharm; 2020 Mar; 77(7):568-573. PubMed ID: 32207821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of a pharmacist-led naloxone coprescribing program in primary care.
    Cariveau D; Fay AE; Baker D; Fagan EB; Wilson CG
    J Am Pharm Assoc (2003); 2019; 59(6):867-871. PubMed ID: 31466899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
    Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
    Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
    Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone for Opioid Overdose and the Role of the Pharmacist.
    Toderika Y; Williams S
    Consult Pharm; 2018 Feb; 33(2):98-104. PubMed ID: 29409576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neighborhood-Level and Spatial Characteristics Associated with Lay Naloxone Reversal Events and Opioid Overdose Deaths.
    Rowe C; Santos GM; Vittinghoff E; Wheeler E; Davidson P; Coffin PO
    J Urban Health; 2016 Feb; 93(1):117-30. PubMed ID: 26800987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dispensing Naloxone Without a Prescription: Survey Evaluation of Ohio Pharmacists.
    Thompson EL; Rao PSS; Hayes C; Purtill C
    J Pharm Pract; 2019 Aug; 32(4):412-421. PubMed ID: 29478362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
    Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a targeted naloxone coprescribing program in a primary care practice.
    Wilson CG; Rodriguez F; Carrington AC; Fagan EB
    J Am Pharm Assoc (2003); 2017; 57(2S):S130-S134. PubMed ID: 28189537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Legal changes to increase access to naloxone for opioid overdose reversal in the United States.
    Davis CS; Carr D
    Drug Alcohol Depend; 2015 Dec; 157():112-20. PubMed ID: 26507172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
    Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
    Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanding access to naloxone in the United States.
    Doyon S; Aks SE; Schaeffer S; ; ;
    Clin Toxicol (Phila); 2014 Dec; 52(10):989-92. PubMed ID: 25283253
    [No Abstract]   [Full Text] [Related]  

  • 36. Opioids, naloxone, and beyond: The intersection of medication safety, public health, and pharmacy.
    Bratberg JP
    J Am Pharm Assoc (2003); 2017; 57(2S):S5-S7. PubMed ID: 28292503
    [No Abstract]   [Full Text] [Related]  

  • 37. A Laboratory Session to Prepare Pharmacy Students to Manage the Opioid Crisis Situation.
    Donohoe KL; Raghavan A; Tran TT; Alotaibi FM; Powers KE; Frankart LM
    Am J Pharm Educ; 2019 Sep; 83(7):6988. PubMed ID: 31619820
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users.
    Acharya M; Chopra D; Hayes CJ; Teeter B; Martin BC
    Value Health; 2020 Apr; 23(4):451-460. PubMed ID: 32327162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time for Pharmacy Co-dispensing of Naloxone with Prescribed Opioids?
    Wunderlich JR; Engelberg RS; Tofighi B; Schwartz MD
    J Gen Intern Med; 2022 Aug; 37(11):2621-2623. PubMed ID: 35581455
    [No Abstract]   [Full Text] [Related]  

  • 40. The implementation of a naloxone rescue program in university students.
    Panther SG; Bray BS; White JR
    J Am Pharm Assoc (2003); 2017; 57(2S):S107-S112.e2. PubMed ID: 28063773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.